Floatz logo

Technetium Tc-99M Cation, Unspecified

Prostate Cancer

University of California, San FranciscomixturePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

481 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Propofol
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
Flotufolastat F 18
Washington University School of Medicine
Phase 4BB

View all 50 →

Same molecule, other indications

Technetium Tc-99M Cation, Unspecified is also rated in:

metastatic carcinoma in the boneActive
BB
Indicative · Phase 3
67 / 100
View asset →
castration-resistant prostate carcinomaActive
CCC
Indicative · Phase 2
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →